This company seems to have been delisted
Reason: Merged with Sun Pharma
Last recorded trade on: August 23, 2024
Source: https://www.prnewswire.com/news-releases/sun-pharma-completes-taro-merger-302180230.html
Reason: Merged with Sun Pharma
Last recorded trade on: August 23, 2024
Source: https://www.prnewswire.com/news-releases/sun-pharma-completes-taro-merger-302180230.html
Taro Pharmaceutical
TARO
S$55.10
Share price
0.00%
Change (1 day)
3.29%
Change (1 year)
Categories
Taro Pharmaceutical (TARO) - Total assets
Total assets on the balance sheet as of December 2023 : S$2.77 Billion
According to Taro Pharmaceutical's latest financial reports the company's total assets are S$2.77 Billion. A company’s total assets is the sum of all current and non-current assets, such as inventories, cash and cash equivalents, properties and equipment.
Taro Pharmaceutical - Total assets on balance sheet (from 2001 to 2023)
Total assets by year
| Year | Total assets | Change |
|---|---|---|
| 2023-03-31 | S$2.83 B | -3.65% |
| 2022-03-31 | S$2.94 B | -8.95% |
| 2021-03-31 | S$3.23 B | -2.74% |
| 2020-03-31 | S$3.32 B | 15.11% |
| 2019-03-31 | S$2.89 B | -9.37% |
| 2018-03-31 | S$3.19 B | -0.23% |
| 2017-03-31 | S$3.19 B | 8.4% |
| 2016-03-31 | S$2.95 B | 23.62% |
| 2015-03-31 | S$2.38 B | 47.65% |
| 2014-03-31 | S$1.61 B | 17.68% |
| 2013-03-31 | S$1.37 B | |
| 2011-12-31 | S$1.03 B | 43.79% |
| 2010-12-31 | S$0.71 B | -11.35% |
| 2009-12-31 | S$0.80 B | 19.5% |
| 2008-12-31 | S$0.67 B | -2.73% |
| 2007-12-31 | S$0.69 B | 6.81% |
| 2006-12-31 | S$0.65 B | -28.66% |
| 2005-12-31 | S$0.91 B | -19.71% |
| 2004-12-31 | S$1.13 B | 8.53% |
| 2003-12-31 | S$1.04 B | 58.93% |
| 2002-12-31 | S$0.65 B | 15.68% |
| 2001-12-31 | S$0.56 B |
Total Assets for similar companies or competitors
| Company | Total assets | differencediff. | Country |
|---|---|---|---|
 Pfizer PFE | S$266.73 B | 9,516.77% | 🇺🇸 USA |
 Merck MRK | S$147.61 B | 5,221.89% | 🇺🇸 USA |
 Johnson & Johnson JNJ | S$248.32 B | 8,853.07% | 🇺🇸 USA |
 Teva Pharmaceutical Industries TEVA | S$49.25 B | 1,675.86% | 🇮🇱 Israel |
 GlaxoSmithKline GSK | S$100.57 B | 3,525.97% | 🇬🇧 UK |
 Novartis NVS | S$128.14 B | 4,520.10% | 🇨🇭 Switzerland |